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Abstract: Despite the enormous success of combined anti-retroviral therapy, HIV 
infection is still a lifelong disease and continues to spread rapidly worldwide. There is a 
pressing need to develop a treatment that will cure HIV infection. Recent progress in stem 
cell manipulation and advancements in humanized mouse models have allowed rapid 
developments of gene therapy for HIV treatment. In this review, we will discuss two 
aspects of HIV gene therapy using human hematopoietic stem cells. The first is to generate 
immune systems resistant to HIV infection while the second strategy involves enhancing 
anti-HIV immunity to eliminate HIV infected cells.  
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1. Introduction 
The success of antiretroviral therapy in HIV infection has changed the landscape of HIV disease. 
Highly active antiretroviral therapy (HARRT), if initiated before advanced disease stages and if 
properly adhered to, can potently reduce the plasma HIV viral load to low or undetectable levels in 
most patients. This has changed what used to be a universally fatal disease to a potentially chronic 
disease. However, despite this success, antiretroviral therapy is not completely effective; chronic 
inflammation and immune dysfunction often persist and emerging evidence shows that there is cryptic 
viral replication in dispersed lymphoid organs during treatment [1]. These factors, along with toxic 
effects of antiretroviral drugs, have been shown to contribute to the increased risk of non-AIDS 
morbidity and mortality [2,3]. In addition, HAART regimen requires daily intake and many patients 
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cannot maintain the high level of adherence necessary for viral control. Moreover, in resource-limited 
countries, it is difficult for many individuals to have continuous access to treatment.  
Given the limitations of the current therapeutic approaches and the absence of any effective 
vaccination strategy against HIV infection, there is a pressing need to develop a curative treatment. 
Hematopoietic stem cell (HSC) based gene therapies have emerged as a promising direction as these 
long-lived, self renewing progenitor cells could be modified to resist HIV infection [4,5]. If 
successfully engrafted, the modified HSCs would offer continuous, long-term production of 
genetically engineered cells that are resistant to HIV infection and/or have enhanced anti-viral activity 
to clear infected cells. If the host can be repopulated with a HIV-resistant hematopoietic system and 
eliminate all viral reservoirs, then a lifelong cure can be achieved. This review will focus on two 
aspects of HSC gene therapies for HIV infection: engineering HIV resistant cells and engineering cells 
that can target HIV infection. These two strategies represent the cutting edge of current gene therapy 
approached towards HIV infection and, alone or in combination with other strategies, have the 
potential to eradicate HIV.  
2. Engineering HIV Resistant Cells 
By targeting different steps of HIV replication, several approaches are being developed to modify 
HSCs to render them resistant to HIV (Figure 1). These approaches can be grouped into three main 
strategies: The first targets cellular genes necessary for viral replication and for this review we will 
focus mainly on the recent successes in targeting CCR5 co-receptor necessary for viral entry; the 
second strategy directly targets HIV gene expression itself; and lastly, one that introduces genes that 
interfere with HIV replication, such as host restriction factors and fusion inhibitors.  
Figure 1. HIV lifecycle and strategies to engineer HIV-resistant cells. 
 
Viruses 2014, 6  
 
 
3 
2.1. Targeting Expression of Cellular Genes that Are Essential for Viral Replication 
CCR5 is a critical co-receptor for entry of HIV and CCR5-tropic viruses represent the majority of 
transmittable HIV-1 strains [6]. Individuals that are homozygous for a deletion of 32 base pairs of the 
CCR5 gene (Δ32) are largely resistant to HIV infection [7]. Individuals with a single copy of the Δ32 
mutation also have slower disease progression once infected with HIV [8]. The identification of these 
individuals has made CCR5 an attractive anti-viral therapeutic target. For example, the small molecule 
antagonist Maraviroc, an allosteric inhibitor of CCR5/HIV interaction, was developed and proven to be 
a successful entry inhibitor [9]. However, antiviral resistance can develop to this drug; thus a more 
permanent strategy targeting CCR5 would be a more effective approach. 
Targeting CCR5 as a potential treatment for HIV infection was further highlighted by the dramatic 
case of the “Berlin patient”, the first documented patient who was cured of HIV infection. This patient 
had acute myeloid leukemia and had received a bone marrow transplant from a donor who was 
homozygous for CCR5Δ32/Δ32. Following transplantation, the engrafted donor cells appeared to confer 
long-term control of HIV infection as the patient had no detectable HIV years after being off 
combination antiretroviral therapy [10,11]. However, this approach is highly impracticable as a 
common treatment strategy. The chance of finding a human leukocyte antigen-matched, CCR5Δ32/Δ32 
homozygous donor is extremely rare (particularly among non-European groups) and allogeneic stem 
cell transplantation has significant associated morbidities and mortalities, limiting the application of 
this approach to patients with AIDS-associated malignancies as a last resort strategy.  
Gene therapies that modify autologous peripheral blood T cells or HSCs can be used to mimic the 
CCR5Δ32/Δ32 phenotype seen in the Berlin patient. In particular, genetically modified HSCs can be used 
to engineer a HIV-1 resistant immune system that would prevent ongoing viral infection. To that end, 
several gene therapy approaches are being tested to reduce CCR5 expression or disrupt the CCR5 
gene. These include using RNA interference (RNAi) [12], using ribozymes [13] to reduce CCR5 RNA 
levels, or using intrabodies [14] and intrakines [15] to target the CCR5 protein directly. RNA 
interference can be achieved through the stable expression of CCR5 short hairpin RNA (shRNA) from 
lentiviruses. The recent study by Shimizu et al. demonstrated that the transduction of human CD34+ 
hematopoietic cells with a CCR5-specific shRNA expressing lentivirus appeared to have no major 
adverse effect on T cell development in humanized Bone Marrow/Liver/Thymus (BLT) mice. Down 
regulation of CCR5 was found in both human T cells and monocyte/macrophages in systemic 
lymphoid tissues and CCR5 tropic HIV-1 replication was effectively inhibited ex vivo [16].  
An alternative strategy to block CCR5 expression is to directly disrupt its genomic sequence.  
Zinc finger proteins are sequence-specific DNA-binding proteins that can be coupled to a DNA 
endonuclease (termed Zinc finger nucleases, ZFNs) to cut DNA at specific sites. Importantly, ZFNs 
only need to be expressed transiently to achieve permanent disruption of target genes and are therefore 
less likely lead to immune elimination due to antigen presentation [17]. Initial studies by Perez et al. 
showed that transient expression of ZFNs can permanently and specifically disrupt 50% of CCR5 
alleles in a pool of primary T cells [18]. Subsequent study using the humanized mouse model showed 
that CCR5 gene was disrupted in 17% of human CD34+ hematopoietic cells by ZFN via nucleofection 
and the modified cells were successfully engrafted in NOD/SCID/IL2rγnull (NSG) mice. Cells with this 
modification successfully conferred resistance to R5-tropic HIV infection. Strikingly, mice transplanted 
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with ZFN modified cells underwent rapid selection for CCR5−/− cells during HIV infection and had 
significantly lower HIV-1 levels [19]. Based on these promising results, several clinical trials of  
ZFN targeting CCR5 are being evaluated in periphery T cells (clinicaltrials.gov: NCR00842634, 
NCT01044654). A recent study showed that ZFN nuclease delivered by a recombinant adenoviral 
vector effectively disrupted >25% CCR5 gene in protein kinase C (PKC) activator pretreated HSCs 
isolated from granulocyte colony-stimulating factor (CSF)-mobilized adults and these cells underwent 
multi-lineage differentiation in vitro and in vivo [20].  
A potential caveat of CCR5 gene therapy is that it may drive the selection of CXCR4 tropic viruses. 
A study targeting the CXCR4 molecule in peripheral CD4 T cells in the humanized mouse model 
using ZFNs showed that CXCR4 disrupted cells proliferated normally and provided protection from 
CXCR4 tropic HIV-1 [21]. However, CXCR4 is widely expressed on many cell types and plays 
important roles in multiple physiologic processes, such as T cell, B cell, cardiovascular and cerebellar 
development [22]. Thus, CXCR4 may not be a feasible target for HSC based gene therapy.  
2.2. Targeting HIV Gene Expression  
HIV genes that are essential for viral replication can also serve as targets for HIV gene therapy. 
Among them, Tat and Rev are both transactivators and are critical for HIV-1 infectivity. In stem cells, 
HIV tat and its overlapping genes have been targeted using hammerhead ribozymes, which are small 
catalytic RNA molecules engineered to target specific RNA species. A Phase 2 gene therapy trial 
showed that patients that received a tat-vpr-specific ribozyme modified autologous CD34+ cells have 
higher CD4+ T cell counts compared to placebo group but have no statistically significant differences 
in viral load [23]. RNA decoys have also been used to inhibit Tat recognition of HIV TAR (trans-activating 
response region) and inhibit viral replication in vitro [2].  
HIV Rev, the viral regulatory protein that allows the nucleus to cytoplasmic transport of unspliced 
viral RNA, can also be targeted in gene therapy. Dominant mutants or trans-dominant forms of Rev 
have been used to inhibit HIV replication in gene modified cells [2,3,24–26]. Decoy rev responsive 
elements (RREs) have also been tested as potential therapeutic targets and were shown to sequester 
Rev in a clinical trial [4,5,27].  
Based on the pattern of HIV gene expression, different stages of the viral replication cycle can also 
be targeted by RNA interference (RNAi). All viral transcripts, including those encoding tat, rev, gag, 
pol, nef, vif, env, vpr, as well as the LTR, are susceptible to RNAi down regulation in cell lines [6,28]. 
A substantial problem of clinical application of RNAi is the virus’s high mutation rate and the ability 
to escape targeted therapy [7,29]. Therefore, as described previously, targeting cellular factors such as 
CCR5 by RNAi may be a more attractive gene therapy strategy than targeting viral transcripts.  
2.3. Introduction of Genes that Interfere with HIV Replication  
An alternative strategy of HSC modification for HIV gene therapy is to introduce exogenous factors 
that will inhibit key steps of HIV infection. To inhibit HIV entry, a gp41-derived protein, C46, that is 
structurally similar to fusion inhibitor enfuvirtide, was developed and shown to effectively inhibit HIV 
entry [8,30]. Clinical trials in HIV infected patients on antiretroviral therapy with advanced disease 
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and multidrug resistant viruses showed that C46 modified autologous T cells were well tolerated but 
had limited effects on plasma viral load [9,31].  
Certain primate host restriction factors, such as Tripartite motif-containing protein 5 alpha 
(TRIM5α), apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like (APOBEC) 3F and 3G, 
and tetherin are resistant to HIV-mediated inhibition and can prevent HIV infection; thus, they are 
potential candidates for gene therapy. For example, expression of rhesus tripartite TRIM5α, which 
binds to HIV capsid and interferes with the uncoating process, strongly protects human cells from HIV 
infection where the virus has evolved to escape restriction from human TRIM5α [10,32]. However, 
rhesus TRIM5α is not suitable for gene therapy due to its potential immunogenicity in humans. To 
overcome this potential antigenicity, a human-rhesus TRIM5α with a single amino acid substitution of 
the human TRIM5α sequence was created and has been shown to inhibit HIV infection [11,33]. 
CD34+ transduced with this chimeric TRIM5α allowed normal thymocyte differentiation in the SCID-hu 
thy/liv mouse and the modified human thymocytes were protected from HIV infection [12,34]. 
Another primate TRIM5α that can effectively block HIV infection is owl monkey TRIM5α that is 
fused with cyclophilin (cyp) A. A human TRIMcyp was developed and was shown to potently inhibit 
HIV in human T cells and macrophages in vitro and in vivo [13,35].  
Despite the successful preliminary results, introduction of exogenous anti-HIV genes into HSCs 
raises several concerns. One is the expressed protein may be immunogenic and eventually removed by 
immune elimination. The other is insertion of genes with their own promoter raises risk of insertional 
activation of nearby genes [14,36]. Nonetheless, ongoing research of HIV restriction factors has 
revealed an increasing list of anti-HIV genes: from Vif-resistant APBOEC3G [15,37], to Vpu-resistant 
tetherin [16,38] that may be used as new strategies to inhibit HIV by gene therapy.  
2.4. Combination Therapy to Prevent Viral Escape  
Due to the short life-cycle and high error rate nature of HIV replication, the virus mutates rapidly, 
resulting in high genetic variability. Antiviral drugs, when given as mono-therapy, usually only have a 
transient effect on HIV replication and current anti-retroviral therapies rely on the combined effects of 
antiretroviral drugs to defend against the development of resistance. Likewise, gene therapies that have 
a single HIV target are also potentially subject to the development of viral resistance. To this end, 
combined gene therapies that target multiple steps of viral replication are being developed. Several 
group have combined multiple anti-HIV genes into a single lentivirus vector [17,39–42]. One 
interesting approach recently reported by Digiusto et al. used a combination of a tat/rev shRNA, a 
TAR decoy and CCR5 ribozyme. Patients were treated for AIDS-related lymphoma and received 
lentiviral vector-modified autologous CD34+ hematopoetic stem cells through transplantation. The 
procedure was well tolerated and gene modified cells persisted for at least 24 months. However, the 
frequency of gene-modified cells in peripheral blood was too low (less than 0.2%) to see a clinical 
benefit for the patients. Due to obvious ethical concerns, the patients received concurrent HAART 
treatment and transplantation of both transduced and untranduced cells. Approaches that would allow 
selection of transduced cells before transplantation are under investigation and may give rise to a 
higher percentage of transduced cells for engraftment to achieve a sufficient therapeutic level for  
HIV-resistant cells [18,43,44].  
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3. Engineering anti-HIV Immunity  
In addition to engineering cells to become resistant to new HIV infection, immunity also plays 
important roles in controlling HIV infection. Because HIV does not possess the immunogenicity to 
elicit protective responses and directly impairs key components of the immune system, most patients 
cannot develop effective immune responses to control HIV replication [19,45]. Viral persistence and 
latency in various reservoirs in the body are also key elements in maintaining the chronic nature of 
infection and various efforts are being made to attempt to purge or target these cells. Illustrative of the 
issue associated with an ineffective immune response coupled with an HIV purging strategy is seen in 
a recent study by Shan et al. [46]. They found that without proper immune stimulation, HIV-specific 
cytotoxic T lymphocytes cannot kill autologous latently infected resting CD4 T cells that were 
reactivated by histone deactylase inhibitor vorinostat in vitro [46,47]. This raises a critical issue that 
purging latent reservoirs may not be sufficient in eliminating HIV infection and the infected cell may 
return to latency because the host does not have the ability to generate an adequate response against 
HIV and eliminate HIV infected cells.  
Therapeutic vaccines were developed to boost and broaden HIV-1-specific CD4 and CD8 T cell 
responses, but with little success to date [22,48–50]. Conjugation of vaccines to anti-dendritic-cell 
antibodies showed promising result in inducing potent cytotoxic T lymphocyte responses [23,51] and 
is currently being investigated in a clinical trial (NCT01127464). Using autologous monocyte-derived 
dendritic cells (MD-DCs) pulsed with heat inactivated whole HIV as therapeutic vaccine also showed 
positive results in controlling plasma viral loads after antiretroviral therapy interruption [52]. Despite 
an initial reduction in viral loads, all patients that received the MD-DCs in this study had viral loads 
rebound back to detectable levels and overall antiviral immune responses to vaccine waned with time [52]. 
It is possible that preexisting immune responses in these HIV infected individuals may have already 
selected viral immune escape variants early in the infection. These studies highlight the difficulty in 
boosting existing host immunity for HIV elimination. 
Another strategy to enhance host anti-viral immunity is to genetically modify peripheral blood cells 
with a molecularly cloned T cell receptor (TCR) or a chimeric molecule that can redirect cells to target 
HIV antigens. A peptide specific TCR from reactive T cells from infected individuals can be cloned 
and used to modify peripheral cells from the same patient [11,53–55]. In one study, a TCR from a 
patient that had a sustained and robust CTL response against HIV gag SL9 peptide was molecularly 
cloned. When introduced to primary CD8 cells via transfection, the genetically modified CD8 cells 
exhibited enhanced and polyfunctional immune responses against viral antigen and an increased ability 
to control HIV infection [55]. A Phase 1 clinical trial (NCT00991224) is being carried out to study the 
effect of redirecting autologous T cells with SL9 TCR for HIV gene therapy [56]. However, there are 
several pitfalls for redirecting peripheral immunity. First, ex vivo manipulation of the cells significantly 
impacted the lifespan and function of the cells and therefore the modified cells had limited effects once 
re-infused back to the body. Another caveat or risk in these studies was that modifying peripheral T 
cells with a cloned TCR may have resulted in mispairing with endogenously expressed TCR α and β 
chains. Cross pairing of TCRs may produce self-reactive T cells since gene modified cells are not 
subject to normal thymic selection for peripheral tolerance. Lastly, many identified highly effective 
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HIV-specific cytotoxic T lymphoctyes are restricted by uncommon HLA class I alleles such as  
HLA-B*27 and HLA-B*57 and cannot be universally applied [22].  
To circumvent the HLA restriction of these molecularly cloned TCRs, an HIV specific chimeric 
antigen receptor (CAR) was developed that contains the extracellular domain of CD4 receptor (which 
binds to HIV env) and intracellular ζ chain of the T cell receptor (which mediates T cell activation). 
CD4 CAR -modified T cells inhibit viral replication and kill HIV infected cells in vitro and were 
reported to have prolonged survival in vivo [57,58]. However, CD4 CAR-modified T cells are 
susceptible to HIV infection and the level of genetically modified cells in patients drops one year after 
blood transfusion, resulting in a limited anti-HIV effect [58].  
Stem cell based anti-HIV immune therapy, in contrast, could potentially bypass many of the 
problems that previous studies and clinical trials have encountered and have several advantages.  
A stem cell based “redirection” approach with a molecularly cloned TCR or CAR would allow proper 
thymic selection of the modified cells and exclusion of endogenous TCR surface expression, 
eliminating the risk of generating self-reactive TCR through mispairing [59]. In addition, stem cell 
based gene therapy would allow long-lived and renewable immunity capable of continuously 
generating anti-viral cells that could overcome the barriers that prevent HIV eradication. Recently, we 
showed that humanized mice transplanted with human HSCs genetically modified with an anti-HIV 
SL9 TCR were able to significantly suppress viral replication compared to control mice following 
challenged with HIV [60]. The genetic modification of HSCs with a TCR allows the cells to 
differentiate in vivo and the TCR modified stem cells differentiated to mature CD8+ cells in multiple 
tissues [60]. This study highlighted the potential of redirecting anti-HIV immunity using hematopoietic 
stem cells. Current advances in identifying antigen specific TCR may make it possible to molecular 
clone multiple TCR from each patient rapidly [61]. The cloned TCR, which match the patient’s HLA 
type and viral genome, can then be optimized and used to genetically modify patient’s HSCs to allow 
development of enriched and sustained modified CD8+ T cells capable of targeting and potentially 
eradicating HIV infected cells.  
4. Conclusions  
As the safety of gene delivery has improved significantly, gene therapy has become an increasingly 
appealing strategy for treating HIV disease [22]. In particular, research on HSC-based anti-HIV gene 
therapy has shown promising results in attempts to cure HIV disease. The use of genetically modified 
HSCs can potentially generate long lasting, renewable immune cells that are programmed to be either 
resistant to HIV infection or have the enhanced ability to eliminate HIV infected cells. Efforts are also 
directed at combining both of these approaches and attempting to protect engineered HIV-specific 
immune cells from HIV infection. It is expected that the safety of genetically modifying HSCs will 
continue to improve as more development occurs in this approach from other studies, such as cancer 
research [62]. With increasingly more advanced techniques in collecting, expanding, and genetically 
manipulating HSCs, HSCs based gene therapy may ultimately offer a curative therapy for HIV infection.  
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